In clinical trials of HD, ASOs (IONIS-HTTRx) targeting the silencing of mutated huntingtin protein (mHTT) effectively reduced mHTT protein expression (Tabrizi et al., 2019). The gene discussed is HTT; the disease is Huntington disease.